Your DNA could determine which heart drug works best

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Of Amish descent * Age 18 to 75 years * Participant in the Phamacogenomics of Anti-Platelet Intervention (PAPI-1) Study or other Amish Research Center study, or a family member of an Amish Research Center study participant. Exclusion Criteria: * Clopidogrel or ticagrelor allergy * Platelet count \< 100,000 mm3 or \> 500,000 mm3 * Hematocrit (Hct) \< 32% or \> 50% * Blood pressure \> 160/95 mm Hg * Co-existing malignancy * Creatinine \> 2.0 mg/dl * Aspartate transaminase (AST) or alanine transaminase (ALT) \> 2 times the upper limit of normal * Thyroid-stimulating hormone (TSH) \< 0.40 or \> 5.50 mU/L * Pregnant or breast feeding * History of gastrointestinal bleeding, a major life-threatening bleeding event, active pathological bleeding, bleeding diathesis, or coagulopathy * History of stroke or transient ischemic attack, deep vein thrombosis, or atrial fibrillation * History of myocardial infarction, coronary artery bypass surgery, unstable angina, or angioplasty * History of sick sinus syndrome, 2nd or 3rd degree atrioventricular block, or bradycardia-related syncope * Type 1 or Type 2 diabetes mellitus * Surgery in the past 3 months or planned surgery in the next 3 months * Participant cannot willingly and safely discontinue medications that, in the opinion of the study physician would affect the outcomes to be measured for at least 1 week prior to study initiation through completion of the study * Participant is unwilling to discontinue taking vitamins and/or supplements that, in the opinion of the study physician would affect the outcomes to be measured for 1 week prior to the study initiation through the the completion of the study * Any other condition that would place prospective participants at unacceptable risk or render them unable to meet the requirements of the protocol in the opinion of the site investigator